|本期目录/Table of Contents|

[1]汤 俊,刘占伟,石明宏.奥希替尼放疗对EGFR突变阳性NSCLC的临床分析[J].中华肺部疾病杂志,2021,(04):481-483.[doi:10.3877/cma.j.issn.1674-6902.2021.04.020]
点击复制

奥希替尼放疗对EGFR突变阳性NSCLC的临床分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年04期
页码:
481-483
栏目:
临床研究
出版日期:
2021-08-20

文章信息/Info

Title:
-
作者:
汤 俊1; 刘占伟2; 石明宏1
232035 安徽,淮南市东方医院集团肿瘤医院放疗科1 肿瘤内科2
Author(s):
-
关键词:
非小细胞肺癌;  EGFR突变阳性;  局部晚期;  奥希替尼;  强调放疗
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2021.04.020
摘要:
目的 探讨奥希替尼联合强调放疗治疗表皮生长因子受体(EGFR)突变阳性局部晚期非小细胞肺癌的疗效。方法 选取2019年8月至2020年8月医院收治的35例老年EGFR突变阳性局部晚期非小细胞肺癌患者,依照治疗方法不同分为对照组19例和观察组16例。对照组采用强调放疗治疗,观察组采用奥希替尼联合强调放疗治疗,2组均治疗6个周期(21 d为一个周期)后观察近期疗效,并对比2组患者肿瘤体积和癌胚抗原(CEA)水平,生存情况以及不良反应。结果 2组患者治疗6个周期后肿瘤体积均减小(P<0.05),且观察组小于对照组(P<0.05),2组CEA水平均降低(P<0.05),且观察组低于对照组(P<0.05); 治疗6个周期后2组疗效等级分布比较差异显著(P<0.05),且观察组的总有效率高于对照组(P<0.05); 观察组患者中位无进展生存时间(P25,P75)为10(7,11)个月,对照组患者无进展生存时间为7(5,10)个月,2组无进展生存时间比较,差异有统计学意义(P<0.05); 2组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论 奥希替尼联合强调放疗用于治疗EGFR突变阳性局部晚期非小细胞肺癌患者疗效显著,能够延长患者生存时间,且安全可靠。
Abstract:
-

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 West H. Management of oligometastatic disease in advanced non-small cell lung cancer[J]. Clin Chest Med, 2020, 41(2): 249-258.
3 刘伯轩, 陈 成, 刘月光, 等. 免疫细胞化学对胸腔积液中的肺非小细胞癌分类与恶性间皮瘤的鉴别诊断分析[J]. 临床研究, 2020, 28(7): 31-33.
4 Clamon G, Zeitler W, An J, et al. Transformational changes between non-small cell and small cell lung cancer-biological and clinical relevance-a review[J]. Am J Clin Oncol, 2020, 43(9): 670-675.
5 Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study[J]. J Clin Oncol, 2020, 38(2): 115-123.
6 Masood A, Kancha RK, Subramanian J. Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib[J]. Semin Oncol, 2019, 46(3): 271-283.
7 Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019, 41(2): 153-163.
8 Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
9 Nagasaka M, Zhu VW, Lim SM, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC[J]. J Thorac Oncol, 2021, 16(5): 740-763.
10 Zhang R, Wang C, Cui K, et al. Prognostic role of computed tomography textural features in early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy[J]. Cancer Manag Res, 2019, 11(2): 9921-9930.
11 惠福海. 非小细胞肺癌患者肺癌组织和血浆中EGFR外显子19、21的基因突变研究[M]. 沈阳: 沈阳药科大学, 2010: 74-77.
12 张百红, 岳红云. 实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志, 2016, 43(11): 845-847.
13 Bílek O, Holánek M, Berkovcová J, et al. Uncommon EGFR mutations in non-small cell lung cancer and their impact on the treatment[J]. Klin Onkol, 2019, 32(2): 6-12.
14 Hsu PC, Jablons DM, Yang CT, et al. Epidermal growth factor receptor (EGFR)pathway, yes-associated protein(yap)and the regulation of programmed death-ligand 1(PD-L1)in non-small cell lung cancer(NSCLC)[J]. Int J Mol Sci, 2019, 20(15): 3821-3829.
15 Nagano T, Tachihara M, Nishimura Y. Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer[J]. Curr Cancer Drug Targets, 2019, 19(8): 595-630.
16 Xia WY, Feng W, Zhang CC, et al. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review[J]. Transl Lung Cancer Res, 2020, 9(5): 2120-2136.
17 Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725-737.
18 Planchard D. Adjuvant osimertinib in EGFR-mutated non-small-cell lung cancer [J]. N Engl J Med, 2020, 383(18): 1780-1782.
19 Aguiar PN Jr, Haaland B, Park W, et al. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(8): 1080-1084.
20 贺新爱, 马 馨, 郜娜娜. 奥希替尼脂质体治疗NSCLC小鼠的疗效及对其免疫功能、生存时间的影响[J]. 临床肺科杂志, 2018, 23(4): 613-616.
21 侯志华, 魏 晗, 魏红艳, 等. 奥希替尼联合颅脑放疗治疗非小细胞肺癌脑转移效果观察[J]. 河北医科大学学报, 2020, 41(6): 14-17.
22 Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib[J]. JAMA Oncol, 2018, 4(11): 1527-1534.
23 Taniguchi H, Yamada T, Wang R, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells[J]. Nat Commun, 2019, 10(1): 259-264.
24 Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase Ⅱ trial(KCSG-LU15-09)[J]. J Clin Oncol, 2020, 38(5): 488-495.
25 Mezquita L, Varga A, Planchard D. Safety of osimertinib in EGFR-mutated non-small cell lung cancer[J]. Expert Opin Drug Saf, 2018, 17(12): 1239-1248.
26 Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(9): 841-849.

备注/Memo

备注/Memo:
基金项目: 安徽省科技攻关计划项目(No.1501042214)
通信作者: 汤 俊, Email: h156879@126.com
更新日期/Last Update: 2021-08-20